Related Experiment Video
Updated: Jul 12, 2025

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke
Published on: January 18, 2018
Antithrombotic and Lipid Lowering Therapy is Associated With Improved Survival After Vascular Surgery: A Population
Martin Altreuther1, Arne Seternes2, Turi Saltnes3
1Section of Vascular Surgery, Department of Surgery, Trondheim University Hospital, St Olavs Hospital, Trondheim, Norway; Department of Circulation and Medical Imaging, Norwegian University of Science and Technology, Trondheim, Norway; Norwegian Registry for Vascular surgery (NORKAR), Department of Medical Quality Registries, St Olavs hospital, Trondheim University Hospital, Trondheim, Norway.
Insights
Combined lipid-lowering drugs and antiplatelet/anticoagulant therapy significantly improved long-term survival after vascular surgery. Patients with lower extremity arterial disease (LEAD) saw the greatest survival benefit from these recommended medications.
Area of Science:
- Cardiovascular Medicine
- Pharmacology
- Public Health
Background:
- Vascular surgery aims to improve outcomes for conditions like carotid stenosis, abdominal aortic aneurysm (AAA), and atherosclerotic lower extremity arterial disease (LEAD).
- Optimizing post-operative medical management, including pharmacotherapy, is crucial for long-term patient survival.
Purpose of the Study:
- To investigate the association between combined lipid-lowering drugs and antiplatelet or anticoagulation therapy and long-term survival following vascular surgery.
- To assess the impact of recommended medications on survival across different vascular conditions and patient demographics.
Main Methods:
- Retrospective cohort study of patients undergoing vascular surgery in Norway (2015-2019).
- Analysis included patients with carotid stenosis, AAA, and LEAD discharged alive.
- Survival was assessed using Kaplan-Meier analysis and multivariable Cox regression, stratified by treatment and medication adherence.
Main Results:
- Patients receiving recommended medications (lipid-lowering drugs plus antiplatelets or anticoagulants) upon discharge showed superior survival across all treatment groups.
- The greatest survival difference was observed in patients with LEAD, with mean survival periods of 4.33 years vs. 3.7 years.
- Cox regression revealed significantly lower mortality rates for patients on recommended medications for LEAD (HR 0.58) and AAA (HR 0.57).
Conclusions:
- Recommended medications are associated with improved survival in both sexes and across all vascular surgery treatment groups.
- The survival benefit was statistically significant for patients with LEAD and AAA, with LEAD patients experiencing the most substantial improvement.
- Adherence to recommended secondary prophylaxis, particularly for patients with LEAD, is strongly emphasized for enhanced long-term outcomes.
Objective:
This population based retrospective cohort study aimed to investigate the association between combined treatment with lipid lowering drugs and antiplatelet or anticoagulation therapy and long term survival following vascular surgery in Norway.
Methods:
The study included all patients who were registered for the treatment of carotid stenosis, abdominal aortic aneurysm (AAA), and atherosclerotic lower extremity arterial disease (LEAD) in the Norwegian Registry for Vascular Surgery between 2015 and 2019 and who were discharged alive. Clinical and medication details were retrieved from the register. Survival was assessed with Kaplan-Meier analysis and a multivariable Cox regression model. Stratification was according to treatment group, patient sex, and if patients received the recommended medications or not. Recommended medications were defined as lipid lowering drugs, usually statins, and antiplatelets, or sometimes anticoagulants, when comorbidity indicated anticoagulation therapy.
Results:
In total, 15 810 patients had LEAD, 4 080 patients AAA, and 2 194 patients had carotid stenosis. In all treatment groups, survival was superior for patients who used the recommended medications upon discharge. The difference was greatest in patients with LEAD with mean survival periods of 4.33 (95% CI 4.29 - 4.36) and 3.7 (95% CI 3.64 - 3.77) years in patients discharged with and without the recommended medications, respectively (p < .001). The mean survival periods were 4.67 (95% CI 4.61 - 4.73) and 4.34 (95% CI 4.24 - 4.44) years in patients with AAA discharged with and without the recommended medications, respectively (p < .001). Cox regression analysis showed a statistically significantly lower mortality rate for patients discharged with the recommended medications for LEAD (HR 0.58; p < .001) and AAA (HR 0.57; p < .001).
Conclusion:
The recommended medications were associated with improved survival in all treatment groups and both sexes. The survival difference was statistically significant in patients with LEAD and AAA. Patients with LEAD had the greatest improvement; therefore, the recommended secondary prophylaxis is especially important in these patients.
More Related Videos
Related Concept Videos
Venous Thrombosis III: Interprofessional Care
Peripheral Artery Disease V: Postoperative Nursing Management
Atherosclerosis III: Management
Peripheral Artery Disease III: Interprofessional Care
Venous Thrombosis IV: Nursing Management
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...

